Springer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand,
Drugs. 2015 Sep;75(13):1547-57. doi: 10.1007/s40265-015-0457-z.
Empagliflozin/linagliptin (Glyxambi(®)) is a once-daily sodium glucose co-transporter type 2 (SGLT2) inhibitor and dipeptidyl peptidase (DPP)-4 inhibitor fixed-dose combination product that is approved in the USA as an adjunct to diet and exercise in adults with type 2 diabetes (T2D) when treatment with both empagliflozin and linagliptin is appropriate. This article reviews the clinical efficacy and tolerability of oral empagliflozin/linagliptin in patients with T2D and summarizes the pharmacological properties of the agents. Results of two randomized controlled trials of 52 weeks' duration in adults with T2D demonstrated that empagliflozin/linagliptin improved glycaemic control significantly more than linagliptin when administered as initial therapy (whereas results vs. empagliflozin were mixed in this setting) and significantly more than linagliptin or empagliflozin when administered as an add-on therapy to metformin. In addition to glycaemic control, empagliflozin/linagliptin provided significant weight loss compared with linagliptin in both trials. Empagliflozin/linagliptin was generally well tolerated in patients with T2D, with a low risk of hypoglycaemia and no reports of exacerbations of, or hospitalizations for, heart failure during the trials. As the first SGLT2 inhibitor/DPP-4 inhibitor fixed-dose combination available, empagliflozin/linagliptin is a useful new option for patients with T2D.
恩格列净/利拉利汀（甘精胰岛素/利拉利汀）是一种每日一次的钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂和二肽基肽酶-4（DPP-4）抑制剂固定剂量复方制剂，在美国被批准作为饮食和运动的辅助治疗，用于 2 型糖尿病（T2D）成人患者，当恩格列净和利拉利汀的治疗都适用时。本文回顾了恩格列净/利拉利汀在 T2D 患者中的临床疗效和耐受性，并总结了这些药物的药理学特性。两项为期 52 周的成人 T2D 随机对照试验的结果表明，与利拉利汀相比，恩格列净/利拉利汀作为初始治疗时显著改善了血糖控制（而在这种情况下，与恩格列净相比结果则不一致），并且作为二甲双胍的附加治疗时也显著优于利拉利汀或恩格列净。除了血糖控制，与利拉利汀相比，恩格列净/利拉利汀在两项试验中均显著减轻了体重。在 T2D 患者中，恩格列净/利拉利汀总体耐受性良好，低血糖风险低，试验期间没有心力衰竭恶化或因心力衰竭住院的报告。作为首个 SGLT2 抑制剂/DPP-4 抑制剂固定剂量复方制剂，恩格列净/利拉利汀是 T2D 患者的一种有用的新选择。
